2026年02月02日，生物股份披露接待调研公告，公司于01月30日接待睿远基金、中信证券、天风证券、 国泰海通证券、招商证券、国投证券等28家机构调研。 生物股份（600201）最新股价为16.28元，较前一交易日收盘价下跌1.77元，跌幅为9.81%，总市值 180.99亿元。从行业市盈率来看，生物股份所处的农药兽药行业滚动市盈率平均47.77倍，行业中值 27.11倍，生物股份179.63倍排名第32位。 调研情况显示，生物股份非洲猪瘟疫苗临床试验进展顺利，于2025年7月取得临床批件，10月启动田间 试验，2026年1月23日完成首次攻毒试验并符合阶段性评价要求，计划4月上旬启动第二轮攻毒试验，6 月完成全部临床试验数据统计与分析。 公司非洲猪瘟疫苗具备显著竞争优势，包括高安全性和高保护性，采用保守性靶点设计对重组毒株、基 因二型毒株均具备较高交叉保护率，已包含完整的妊娠动物安全性实验数据；技术优势方面，公司拥有 大动物P3实验室，已建成专用GMP生产车间并通过验收，在产业化方面具备先发优势；时间壁垒明 显，是率先取得临床批件并完成首次攻毒试验的企业，已完成万头猪只大规模免疫实验。 参与此次调研的睿远 ...

Core Viewpoint - The company has decided to suspend the research and application of the African Swine Fever freeze-dried inactivated vaccine due to uncertainties in project progress and high R&D difficulties [1] Group 1: Company Actions - On January 30, 2026, the company's board of directors approved the suspension of the African Swine Fever vaccine project [1] - The company’s subsidiary, Jinhai Youben, acquired 60% equity of Jilin Youben for 288 million yuan to enter the African Swine Fever vaccine research and production [1] Group 2: Project Status - As of the end of the third quarter of 2025, all relevant qualifications for the project had met the requirements [1] - Disagreements with the patent transferor over key terms have led to uncertainties in project progress [1] Group 3: Financial Implications - The suspension of the project will result in goodwill impairment but will not have a significant adverse impact on existing business operations [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company is a leader in the animal health sector, with a diverse product range including over a hundred vaccines for pigs, poultry, ruminants, and pets. The upcoming launch of the African swine fever vaccine is expected to significantly enhance growth potential. The company has increased its profit forecasts for 2026-2027, projecting net profits of 712 million and 1.211 billion yuan respectively, with corresponding EPS of 0.64 and 1.09 yuan [5][6][7]. Summary by Sections 1. Focus on Animal Health Vaccine Technology - The company has established itself as a leader in the animal health sector, focusing on vaccine technology and expanding its product offerings. It has transitioned from a diversified business model to concentrate on animal health since 2008, becoming a market leader in foot-and-mouth disease vaccines [20][25]. 2. Technical Innovation Builds Core Competitive Barriers - The company emphasizes technical innovation, with R&D investment of 84 million yuan in the first half of 2025, accounting for 13.51% of revenue, positioning it among the top in its industry. The company has over 20 vaccine projects in development and plans to introduce more than 40 new vaccines in the next five years [6][61]. 3. Upcoming Launch of African Swine Fever Vaccine - The company is set to be the first to launch the African swine fever subunit vaccine, which is expected to significantly reduce costs in pig farming. The vaccine is projected to create an additional market space of 8.4 billion yuan annually [7][10]. 4. Stable Foundation for Foot-and-Mouth Disease Vaccine - The company maintains a solid foundation in foot-and-mouth disease vaccines, with a focus on strategic growth in non-foot-and-mouth disease vaccines. The company has seen strong performance in ruminant vaccines and is expanding its pet vaccine offerings [8][9]. 5. Financial Summary and Valuation Indicators - The company’s revenue is projected to grow from 1.361 billion yuan in 2025 to 5.097 billion yuan in 2027, with net profits expected to rise from 188 million yuan to 1.211 billion yuan over the same period. The projected P/E ratios for 2025, 2026, and 2027 are 98.5, 25.9, and 15.3 respectively [10].

Core Viewpoint - The company, Pulaike (603566.SH), emphasizes its research and development capabilities in the veterinary medicine sector, despite concerns about its lag in vaccine development for major diseases like African swine fever compared to competitors. Group 1: R&D Infrastructure - The company has established multiple national and provincial-level innovation platforms, including the National Engineering Research Center for Veterinary Drugs and the National Key Laboratory for Animal Infectious Disease Diagnosis and Vaccine Development [1] - It has built a biosafety level 3 laboratory that is operational and has received approval for activities involving certain pathogenic microorganisms [1] Group 2: Technological Capabilities - The company has developed a comprehensive set of technical platforms over the years, including reverse genetics, prokaryotic and eukaryotic expression technologies, multivalent vaccine technology, high-density fermentation technology, and antigen concentration and purification technology [1] - These platforms enable the company to develop a series of genetically engineered vaccines [1] Group 3: Innovation and Achievements - The company has produced several innovative products that fill gaps in both international and domestic markets, including various inactivated vaccines for poultry and swine [1] - As of now, the company has obtained 81 national new veterinary drug registration certificates, filed over 600 invention patent applications, and received 340 invention patent grants, along with three second-class National Science and Technology Progress Awards [1]

Core Viewpoint - The company reported a significant rebound in performance in Q3 2025, despite facing pressures in the animal health industry due to market competition and price declines in core products [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 1.042 billion yuan, a year-on-year increase of 7.38%, and a net profit attributable to shareholders of 161 million yuan [1]. - In Q3 2025 alone, the company recorded revenue of 423 million yuan, up 17.76% year-on-year, and a net profit of 101 million yuan, representing a substantial increase of 116.40% [1]. Market Position and Strategy - The company maintained a strong market share in core products like foot-and-mouth disease vaccines, despite intense competition and price pressures [2]. - The pet and international segments have shown remarkable performance, becoming key growth drivers for the company [2]. - The company is transitioning from pure product sales to a model that includes professional services and comprehensive solutions, enhancing customer loyalty and ensuring healthy cash flow through strict credit policies [2]. Research and Development - The company invested 96.015 million yuan in R&D in the first three quarters, reflecting a year-on-year increase of 9.08% [2]. - The company has successfully diversified its product structure, reducing reliance on single products and achieving significant sales growth in core vaccines [3]. - The company is focusing on key products like the African swine fever vaccine, which is seen as a critical opportunity in the animal health industry [3]. Technological Advancements - The company established the world's first animal mRNA vaccine production facility, which is a core component of its technological advantage [4]. - The company has multiple mRNA vaccine projects in various stages, including the world's first mRNA vaccine for feline infectious peritonitis, which is expected to generate over 1 billion yuan in sales in its first year [4]. Future Growth Strategy - The company aims to shift from reliance on single products to a multi-business model, with three main growth engines: expanding the pet business, international market penetration, and continuous R&D breakthroughs [5].

Core Viewpoint - The report highlights the strong performance of Keqian Bio in the first half of 2025, driven by increased demand in the animal health sector and the introduction of new products, leading to a buy rating for the company. Group 1: Financial Performance - In the first half of 2025, Keqian Bio achieved revenue of 487 million yuan, a year-on-year increase of 21.7%, and a net profit attributable to shareholders of 220 million yuan, up 44.1% year-on-year [1] - In Q2 2025, the company reported revenue of 242 million yuan, reflecting a year-on-year growth of 23.8%, and a net profit of 110 million yuan, which is a significant increase of 70.8% year-on-year [1] Group 2: Market Demand and Product Sales - The profitability of downstream farming enterprises has improved, leading to an increase in demand for animal health products, with a 17% year-on-year growth in batch approvals in the first half of 2025 [2] - In the first half of 2025, the company's vaccine issuance volume grew by 43% year-on-year, with significant increases in the sales of swine fever, diarrhea, and circovirus vaccines, reaching growth rates of 50%, 85%, and 153% respectively [3] Group 3: Research and Development - The company has increased its R&D investment, with R&D expenses accounting for 9.34% of total expenses by the end of Q2 2025, up 0.2 percentage points from the end of Q4 2024 [4] - New products launched include a dual vaccine for swine fever and pseudorabies, which aims to reduce immunization frequency while effectively preventing two diseases with one injection [4] Group 4: Investment Outlook - The animal health industry is expected to recover as price wars diminish due to the exit of some companies, supported by favorable policies that help control farming losses [5] - Revenue projections for Keqian Bio are estimated at 1.22 billion yuan, 1.31 billion yuan, and 1.57 billion yuan for 2025, 2026, and 2027 respectively, with corresponding net profits of 450 million yuan, 520 million yuan, and 630 million yuan [5]